Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.8046
-0.0816 (-9.21%)
May 27, 2025, 3:37 PM - Market open
Prelude Therapeutics Stock Forecast
PRLD's stock price has decreased by -78.64% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Prelude Therapeutics stock ranges from a low of $4.00 to a high of $5.00. The average analyst price target of $4.50 forecasts a 459.28% increase in the stock price over the next year.
Price Target: $4.50 (+459.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prelude Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +521.43% | May 5, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $4 | Buy | Reiterates | $4 | +397.14% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +521.43% | Apr 8, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $4 | Buy | Reiterates | $4 | +397.14% | Mar 12, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $7 → $4 | Buy | Reiterates | $7 → $4 | +397.14% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
n/a
from 7.00M
Revenue Next Year
n/a
EPS This Year
-1.69
from -1.68
EPS Next Year
-1.22
from -1.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.29 | -0.41 | -0.27 | ||
| Avg | -1.69 | -1.22 | -0.92 | ||
| Low | -1.90 | -1.65 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.